fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

EU gives green light for new medicines

Written by | 12 May 2021

Article written by Gary Finnegan. The European Medicines Agency’s (EMA) key committee, known as the CHMP, has recommended approval of eight medicines at its latest meeting. While the… read more.

Novel pharmacological strategies to treat alcoholism. Focus on epigenetics

Written by | 11 Apr 2021

Abusive alcohol drinking considerably impacts human health. Alcoholism, better defined as Alcohol Use Disorders (AUD), includes a group of pathological entities related to alcohol-induced damage. Individuals with AUD… read more.

Community pharmacy input to Vac4covid

Written by | 8 Apr 2021

Interview and article by Christine Clark. Community pharmacies are at the heart of their communities and can contribute to the Vac4covid study by signposting patients to the website,… read more.

How the Vac4covid study will collect data

Written by | 7 Apr 2021

Interview and article by Christine Clark. Gavin Dobson, Clinical Trials Pharmacist at MEMO Research explains the practical details of the Vac4covid study. The Vac4covid study will recruit at… read more.

Studying people’s experience of covid-19 vaccination – Vac4covid

Written by | 6 Apr 2021

Interview and article by Christine Clark. The Vac4covid study has been designed to provide important data about the safety and effectiveness of covid-19 vaccines. IMI interviewed Mr Gavin… read more.

ASHP publishes reports exploring pharmacy’s role in future of healthcare delivery

Written by | 1 Apr 2021

ASHP (American Society of Health-System Pharmacists) today announced the publication of two landmark reports that articulate a futuristic vision for pharmacy practice, including expanded roles for the pharmacy enterprise… read more.

AbbVie announces extension of review for supplemental NDA of upadacitinib to treat psoriatic arthritis

Written by | 26 Mar 2021

AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic… read more.

EMA backs six new medicines

Written by | 14 Mar 2021

Article written by Gary Finnegan. The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six medicines for approval at its February 2021 meeting:

TicoVac filed with FDA for tick-borne encephalitis – Pfizer

Written by | 2 Mar 2021

Pfizer announced that the FDA accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac, its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE… read more.

Amgen submits supplemental NDA for Otezla for adults with mild-to-moderate plaque psoriasis

Written by | 1 Mar 2021

Amgen announced the submission of a supplemental New Drug Application (sNDA) to the FDA for Otezla (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are… read more.

EU approves Yuflyma for multiple chronic inflammatory diseases – Celltrion Healthcare

Written by | 28 Feb 2021

Celltrion Healthcare announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the… read more.

Medtronic announces voluntary recall of unused Valiant Navion Thoracic stent graft system

Written by | 24 Feb 2021

Medtronic plc has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent graft system and informed physicians to immediately cease use of the device until… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.